Cell Biotech Co., Ltd. (KOSDAQ:049960)

Cell Biotech Balance Sheet

Financials in millions KRW. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	4,757	7,884	8,458	9,860	9,600
Short-Term Investments	74,450	56,515	37,671	18,675	23,084
Trading Asset Securities	8,247	5,933	19,239	29,299	22,203
Cash & Short-Term Investments	87,454	70,332	65,368	57,834	54,887
Cash Growth	24.34%	7.59%	13.03%	5.37%	-7.32%
Accounts Receivable	3,991	4,595	4,566	4,664	4,835
Other Receivables	682.88	943.86	583.11	268.43	283.39
Receivables	4,976	5,740	5,330	5,216	5,557
Inventory	4,203	4,122	4,102	3,589	3,503
Prepaid Expenses	287.27	691.85	500.5	292.5	218.67
Other Current Assets	228.19	1,044	354.58	587.81	746.72
Total Current Assets	97,148	81,929	75,655	67,519	64,913
Property, Plant & Equipment	30,463	32,937	33,638	34,057	36,602
Long-Term Investments	501.94	501.94	3,786	8,427	2
Other Intangible Assets	1,606	1,599	1,793	1,536	1,802
Long-Term Accounts Receivable	0	0	0	0	0
Long-Term Deferred Tax Assets	216.96	182.29	449.3	751.56	1,395
Other Long-Term Assets	461.66	491.37	517.21	585.15	587.54
Total Assets	130,398	117,641	115,839	112,877	105,301
Accounts Payable	680.27	578.39	1,370	1,224	887.65
Accrued Expenses	481.51	489.15	443.91	470.95	496.32
Current Portion of Leases	650.28	621.14	600.78	402.89	658.65
Current Income Taxes Payable	1,404	-	1,038	814.73	-
Current Unearned Revenue	27.57	27.03	30.9	50.44	41.52
Other Current Liabilities	2,619	3,106	3,905	2,802	2,546
Total Current Liabilities	5,863	4,821	7,389	5,766	4,630
Long-Term Leases	366.66	934.17	357.79	423.49	686.44
Other Long-Term Liabilities	-	-	-	0	-
Total Liabilities	6,229	5,755	7,747	6,189	5,317
Common Stock	4,700	4,700	4,700	4,700	4,700
Additional Paid-In Capital	12,760	12,760	12,760	12,760	12,760
Retained Earnings	130,264	118,217	114,993	109,894	102,696
Treasury Stock	-23,978	-23,978	-23,978	-20,258	-20,258
Comprehensive Income & Other	422.69	186.4	-382.91	-408.42	86.97
Shareholders' Equity	124,168	111,885	108,092	106,687	99,985
Total Liabilities & Equity	130,398	117,641	115,839	112,877	105,301
Total Debt	1,017	1,555	958.57	826.38	1,345
Net Cash (Debt)	86,437	68,777	64,409	57,007	53,542
Net Cash Growth	25.68%	6.78%	12.98%	6.47%	-8.16%
Net Cash Per Share	12628.32	10048.59	9342.06	8061.43	7547.42
Filing Date Shares Outstanding	6.84	6.84	6.84	7.07	7.07
Total Common Shares Outstanding	6.84	6.84	6.84	7.07	7.09
Working Capital	91,286	77,108	68,266	61,754	60,283
Book Value Per Share	18142.94	16348.17	15793.91	15086.68	14094.07
Tangible Book Value	122,563	110,286	106,299	105,151	98,183
Tangible Book Value Per Share	17908.31	16114.53	15531.88	14869.49	13840.05
Land	9,696	9,765	9,765	9,765	9,784
Buildings	19,675	19,537	13,349	13,854	14,389
Machinery	25,847	25,644	7,228	8,033	9,682
Construction In Progress	385.42	338.95	993.9	247.26	95

Updated Nov 14, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.